Thursday, February 2 at 1 PM ET
Yesterday the Duchenne community learned that Part B of the MoveDMD trial did not meet its primary endpoint, which was to demonstrate a statistically significant decrease in T2 MRI with edasalonexent after 12 weeks compared to placebo in people affected by Duchenne. There were some potential treatment-associated effects at 12 weeks in the 100 mg/kg/day treatment group when compared to placebo. Therefore, Catabasis will look to see if the signals strengthen in the longer-term data from the ongoing open-label extension.
The Catabasis team will speak to our community on Thursday, February 2 at 1 PM ET to discuss what they learned from this latest trial and what comes next in the MoveDMD program.
Please submit all questions to email@example.com (subject line: Catabasis Webinar) no later than 4 PM ET on Wednesday, February 1.
Please submit questions in advance to firstname.lastname@example.org, with “Catabasis Webinar” in the subject line by 4 PM ET on Wednesday, February 1.